MorphoSys initiates phase 1b clinical trial with MOR103
Posted: Wed Dec 21, 2011 12:22 am
MorphoSys AG announced today that a phase 1b clinical trial evaluating MOR103, a human monoclonal antibody to GM-CSF (granulocyte macrophage-colony stimulating factor), in patients with multiple sclerosis (MS) is now open for enrollment, thereby adding a second indication to the development program.
A phase 1b/2a trial in patients with active rheumatoid arthritis is ongoing and is on track to report data by mid of 2012. Additionally, a phase 1 pharmacokinetic (PK) study in healthy volunteers to evaluate a subcutaneous formulation of MOR103 will commence shortly....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397